FATE
Price
$1.07
Change
+$0.05 (+4.90%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
117.66M
47 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$4.85
Change
+$0.16 (+3.41%)
Updated
Jan 14 closing price
Capitalization
2.52B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs RXRX

Header iconFATE vs RXRX Comparison
Open Charts FATE vs RXRXBanner chart's image
Fate Therapeutics
Price$1.07
Change+$0.05 (+4.90%)
Volume$59.41K
Capitalization117.66M
Recursion Pharmaceuticals
Price$4.85
Change+$0.16 (+3.41%)
Volume$16.95M
Capitalization2.52B
FATE vs RXRX Comparison Chart in %
View a ticker or compare two or three
VS
FATE vs. RXRX commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (FATE: $1.08 vs. RXRX: $4.85)
Brand notoriety: FATE and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 106% vs. RXRX: 73%
Market capitalization -- FATE: $124.58M vs. RXRX: $2.52B
FATE [@Biotechnology] is valued at $124.58M. RXRX’s [@Biotechnology] market capitalization is $2.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, RXRX is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • FATE’s TA Score: 5 bullish, 4 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both FATE and RXRX are a good buy in the short-term.

Price Growth

FATE (@Biotechnology) experienced а -2.70% price change this week, while RXRX (@Biotechnology) price change was -0.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

FATE is expected to report earnings on Mar 02, 2026.

RXRX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.52B) has a higher market cap than FATE($118M). RXRX YTD gains are higher at: 18.582 vs. FATE (3.806). FATE has higher annual earnings (EBITDA): -145.34M vs. RXRX (-636.09M). RXRX has more cash in the bank: 660M vs. FATE (215M). FATE (79.2M) and RXRX (82.4M) have identical debt. RXRX has higher revenues than FATE: RXRX (43.4M) vs FATE (7.14M).
FATERXRXFATE / RXRX
Capitalization118M2.52B5%
EBITDA-145.34M-636.09M23%
Gain YTD3.80618.58220%
P/E RatioN/AN/A-
Revenue7.14M43.4M16%
Total Cash215M660M33%
Total Debt79.2M82.4M96%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
12
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
82
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATERXRX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ODMCX10.040.06
+0.60%
JPMorgan SMID Cap Equity C
EISIX33.120.06
+0.18%
Carillon ClariVest Intl Stock I
RMOMX25.32-0.09
-0.35%
Victory RS Mid Cap Growth Member
MSALX25.70-0.17
-0.66%
Morgan Stanley Inst Intl Advtg L
FGSRX133.99-0.96
-0.71%
Franklin Growth R

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with CRBU. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-4.67%
CRBU - FATE
49%
Loosely correlated
+0.63%
MGX - FATE
47%
Loosely correlated
-1.71%
RXRX - FATE
47%
Loosely correlated
-2.49%
ALLO - FATE
46%
Loosely correlated
-1.80%
NKTX - FATE
45%
Loosely correlated
-5.96%
More